Learned screening identifies early antiviral candidates with enzyme and cell-entry assay activity
Source check: Source checked. Not independent scientific confirmation.
Finding: A two-stage learned screen combined SchNet molecular representations with XGBoost to prioritize compounds for laboratory evaluation. Follow-up assays identified early candidates with protease-inhibition and cell-entry activity, with additional cell and human-airway tissue-model tests. These are moderate-potency laboratory hits; direct target binding, clinical benefit and reduced resistance were not established.
Technology: SchNet molecular graph classification; XGBoost candidate prioritization
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
- AI contribution
- SchNet learns molecular representations from prior screening measurements and filters library compounds; a second learned XGBoost layer incorporates descriptors to prioritize candidates before new laboratory measurements.
- Test and result
- The learned screen prioritized roughly 500 compounds from about 170000 library entries. The source reports 27 initial follow-up hits and examines a smaller representative subset using enzyme, cell-entry, cell-based and 3D airway-tissue assays. Four of eight detailed representatives showed moderate protease inhibition; others primarily showed entry-assay activity.
- Limitation / still unknown
- This is not evidence that every hit has a confirmed dual mechanism. Direct specific target binding remains unconfirmed; aggregation or protein-destabilization artifacts were not excluded. Some tissue-model effects coincide with cytotoxicity, and incomplete inhibition complicates potency estimates. Reduced resistance, patient efficacy and a clinical therapeutic window were not tested. The current readable journal version is represented; the publisher version-history endpoint was rate-limited, so exact timing of any later text updates is unresolved.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.mdpi.com/1420-3049/31/6/1043
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 21 Nov 2026. Review scope: Exact primary front DOI/title/date and fresh primary notice metadata; computational model/data Methods and high-level assay results/limitations read. No operational pathogen procedures represented or archived in the case evidence..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.